N1 Research LLC
Welcome,         Profile    Billing    Logout  
 13 Trials 
34 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rodriguez, Ramon
IPX203-401-23, NCT06765668: A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Recruiting
4
220
US
CREXONT ER, IPX203
Impax Laboratories, LLC, Amneal Pharmaceuticals, LLC
Parkinson Disease
11/25
08/26
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
AbbVie
Parkinson Disease
01/24
02/24
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
304
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
AbbVie
Parkinson Disease
10/24
10/24
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
01/25
02/25
NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting
2
150
US
NEU-411, Placebo
Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
09/26
09/27
NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting
N/A
82
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
02/26
02/26
Isaacson, Stuart
IPX203-401-23, NCT06765668: A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Recruiting
4
220
US
CREXONT ER, IPX203
Impax Laboratories, LLC, Amneal Pharmaceuticals, LLC
Parkinson Disease
11/25
08/26
LIGHTHOUSE, NCT05418673 / 2022-000747-77: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Terminated
3
7
Europe, US
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
07/23
07/23
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
AbbVie
Parkinson Disease
01/24
02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
522
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
06/24
06/24
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated
3
1125
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
12/24
12/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
NCT03655236: PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Terminated
2
513
Europe, US, RoW
K0706, placebo
Sun Pharma Advanced Research Company Limited
Early Parkinson Disease
04/24
06/24
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

Completed
2
130
US
CT1812
Cognition Therapeutics, National Institute on Aging (NIA)
Dementia With Lewy Bodies
11/24
11/24
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
01/25
02/25
LRRK2-PD, NCT06602193: Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease

Recruiting
2
50
Europe, US
BIIB122 225 mg, DNL151, BIIB122-Matching Placebo
Denali Therapeutics Inc., Biogen
Parkinson Disease
04/26
02/28
NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting
2
150
US
NEU-411, Placebo
Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
09/26
09/27
LUMA, NCT05348785 / 2021-004849-20: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

Active, not recruiting
2
650
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Active, not recruiting
2
92
Japan, US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26
NCT04680065: GDNF Gene Therapy for Multiple System Atrophy

Recruiting
1
9
US
AAV2-GDNF gene therapy, Sham (Placebo) Surgery
Brain Neurotherapy Bio, Inc.
Multiple System Atrophy
12/25
12/28
NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting
N/A
82
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
02/26
02/26
TRANQUIL, NCT06235190: Assessment of the Safety and Efficacy of the Felix NeuroAI Wristband in Essential Tremor

Active, not recruiting
N/A
126
US, RoW
Felix NeuroAI Wristband, Sham Device
Fasikl Inc.
Essential Tremor
10/24
11/25
NCT05699460: Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

Active, not recruiting
N/A
150
Europe, US
This is an observational study.
Asklepios Biopharmaceutical, Inc.
Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
08/25
10/25
ROPAD, NCT03866603: Rostock International Parkinson's Disease Study

Active, not recruiting
N/A
25000
Europe, Canada, US, RoW
CENTOGENE GmbH Rostock
Parkinson´s Disease
12/25
12/25
Acosta, Carem
NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting
2
150
US
NEU-411, Placebo
Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
09/26
09/27
MTR-601-201, NCT06830642: Study of the Oral Treatment MTR-601 in Cervical Dystonia

Recruiting
2
80
US
MTR-601, Placebo
Motric Bio
Cervical Dystonia
07/26
08/26
NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting
N/A
82
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
02/26
02/26
Arias, Karla
REGENERATE-PD, NCT06285643: A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease

Recruiting
2
87
Europe, US
AAV2-GDNF Gene therapy, Biological, Control Surgery
AskBio Inc, Bayer
Parkinson Disease
11/27
11/27
NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting
2
150
US
NEU-411, Placebo
Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
09/26
09/27
NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting
N/A
82
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
02/26
02/26
Santoni, Erica
NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting
N/A
82
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
02/26
02/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rodriguez, Ramon
IPX203-401-23, NCT06765668: A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Recruiting
4
220
US
CREXONT ER, IPX203
Impax Laboratories, LLC, Amneal Pharmaceuticals, LLC
Parkinson Disease
11/25
08/26
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
AbbVie
Parkinson Disease
01/24
02/24
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
304
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
AbbVie
Parkinson Disease
10/24
10/24
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
01/25
02/25
NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting
2
150
US
NEU-411, Placebo
Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
09/26
09/27
NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting
N/A
82
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
02/26
02/26
Isaacson, Stuart
IPX203-401-23, NCT06765668: A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Recruiting
4
220
US
CREXONT ER, IPX203
Impax Laboratories, LLC, Amneal Pharmaceuticals, LLC
Parkinson Disease
11/25
08/26
LIGHTHOUSE, NCT05418673 / 2022-000747-77: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Terminated
3
7
Europe, US
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
07/23
07/23
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
AbbVie
Parkinson Disease
01/24
02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
522
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
06/24
06/24
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated
3
1125
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
12/24
12/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
NCT03655236: PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Terminated
2
513
Europe, US, RoW
K0706, placebo
Sun Pharma Advanced Research Company Limited
Early Parkinson Disease
04/24
06/24
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

Completed
2
130
US
CT1812
Cognition Therapeutics, National Institute on Aging (NIA)
Dementia With Lewy Bodies
11/24
11/24
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
01/25
02/25
LRRK2-PD, NCT06602193: Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease

Recruiting
2
50
Europe, US
BIIB122 225 mg, DNL151, BIIB122-Matching Placebo
Denali Therapeutics Inc., Biogen
Parkinson Disease
04/26
02/28
NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting
2
150
US
NEU-411, Placebo
Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
09/26
09/27
LUMA, NCT05348785 / 2021-004849-20: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

Active, not recruiting
2
650
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Active, not recruiting
2
92
Japan, US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26
NCT04680065: GDNF Gene Therapy for Multiple System Atrophy

Recruiting
1
9
US
AAV2-GDNF gene therapy, Sham (Placebo) Surgery
Brain Neurotherapy Bio, Inc.
Multiple System Atrophy
12/25
12/28
NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting
N/A
82
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
02/26
02/26
TRANQUIL, NCT06235190: Assessment of the Safety and Efficacy of the Felix NeuroAI Wristband in Essential Tremor

Active, not recruiting
N/A
126
US, RoW
Felix NeuroAI Wristband, Sham Device
Fasikl Inc.
Essential Tremor
10/24
11/25
NCT05699460: Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

Active, not recruiting
N/A
150
Europe, US
This is an observational study.
Asklepios Biopharmaceutical, Inc.
Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
08/25
10/25
ROPAD, NCT03866603: Rostock International Parkinson's Disease Study

Active, not recruiting
N/A
25000
Europe, Canada, US, RoW
CENTOGENE GmbH Rostock
Parkinson´s Disease
12/25
12/25
Acosta, Carem
NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting
2
150
US
NEU-411, Placebo
Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
09/26
09/27
MTR-601-201, NCT06830642: Study of the Oral Treatment MTR-601 in Cervical Dystonia

Recruiting
2
80
US
MTR-601, Placebo
Motric Bio
Cervical Dystonia
07/26
08/26
NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting
N/A
82
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
02/26
02/26
Arias, Karla
REGENERATE-PD, NCT06285643: A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease

Recruiting
2
87
Europe, US
AAV2-GDNF Gene therapy, Biological, Control Surgery
AskBio Inc, Bayer
Parkinson Disease
11/27
11/27
NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting
2
150
US
NEU-411, Placebo
Neuron23 Inc., Qiagen Manchester Limited, Roche Diagnostic Ltd.
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
09/26
09/27
NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting
N/A
82
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
02/26
02/26
Santoni, Erica
NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting
N/A
82
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
02/26
02/26

Download Options